FFO
RXRX icon

Fortitude Family Office’s Recursion Pharmaceuticals RXRX Stock Holding History

Fortitude Family Office’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1,038
Closed -$3.81K – 2724
2026
Q2 		$3.81K Buy
+1,038
New +$3.46K ﹤0.01% 1208
2025
Q3 		– Sell
-87
Closed -$440 – 2115
2025
Q2 		$440 Buy
+87
New +$427 ﹤0.01% 1867
2024
Q3 		– Sell
-81
Closed -$608 – 1263
2024
Q2 		$608 Buy
+81
New +$706 ﹤0.01% 914

Other funds holding RXRX

GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
CCIA
Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return
WWM
Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return
KG
Kieckhefer Group Mequon, Wisconsin $252M AUM 40.97% 1-Year Est. Return
AWM
Accel Wealth Management Waverly, Iowa $464M AUM 21.88% 1-Year Est. Return
OBWG
Onyx Bridge Wealth Group Tarrytown, New York $1.14B AUM 18.43% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
Wedmont Private Capital
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Fortitude Family Office's RXRX Position: Q3 2026 in Review

Fortitude Family Office sold out of Recursion Pharmaceuticals (RXRX) in Q3 2026, closing a stake of 1,038 shares — an estimated $3.81K sold.

Fortitude Family Office first reported a position in RXRX in Q2 2024 and held it in 3 quarters. The position peaked at $3.81K in Q2 2026. 28 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Fortitude Family Office reported no remaining Recursion Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Fortitude Family Office sold 1,038 Recursion Pharmaceuticals shares in Q3 2026, an estimated $3.81K.
  • Fortitude Family Office first reported a position in Recursion Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Fortitude Family Office's Recursion Pharmaceuticals position peaked at $3.81K in Q2 2026.
  • 28 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.